Manufacturing Compliance Updates In Brief From US FDA and EU
Executive Summary
Recent US FDA drug GMP warning letters target data integrity issues, inadequate sterility practices and inadequate testing of raw materials and finished products at firms in Japan, Hong Kong, China, Italy and the US; FDA adds one drug GMP import alert; and EU GMP noncompliance notice goes to Kadam Exports in India for deficient manufacturing conditions.